EGFR activation limits the response of liver cancer to lenvatinib

Hepatocellular carcinoma (HCC)—the most common form of liver cancer—is an aggressive malignancy with few effective treatment options 1 . Lenvatinib is a small-molecule inhibitor of multiple receptor tyrosine kinases that is used for the treatment of patients with advanced HCC, but this drug has only...

Full description

Saved in:
Bibliographic Details
Published in:Nature (London) Vol. 595; no. 7869; pp. 730 - 734
Main Authors: Jin, Haojie, Shi, Yaoping, Lv, Yuanyuan, Yuan, Shengxian, Ramirez, Christel F. A., Lieftink, Cor, Wang, Liqin, Wang, Siying, Wang, Cun, Dias, Matheus Henrique, Jochems, Fleur, Yang, Yuan, Bosma, Astrid, Hijmans, E. Marielle, de Groot, Marnix H. P., Vegna, Serena, Cui, Dan, Zhou, Yangyang, Ling, Jing, Wang, Hui, Guo, Yuchen, Zheng, Xingling, Isima, Nikita, Wu, Haiqiu, Sun, Chong, Beijersbergen, Roderick L., Akkari, Leila, Zhou, Weiping, Zhai, Bo, Qin, Wenxin, Bernards, René
Format: Journal Article
Language:English
Published: London Nature Publishing Group UK 29.07.2021
Nature Publishing Group
Subjects:
ISSN:0028-0836, 1476-4687, 1476-4687
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first